Current issue
Archive
Online first
About the Journal
Editorial Office
Editorial Board
Publisher
Editorial Policies
Ethical standards and procedures
Abstracting and indexing
Reviewers
Honorary Reviewers
Subscription
Contact
Most read articles
Instructions for authors
Article processing charge (APC)
Books and Events
Books
Events
ORIGINAL PAPER
zwyrodnieniowej stawów Usefulness of measurement of serum COMP and C2C level in end-stage osteoarthritis
Online publication date: 2009-03-31
Reumatologia 2009;47(1):15-19
KEYWORDS
ABSTRACT
Background: The aim of the study was to evaluate the level of COMP and C2C in serum end-stage osteoarthritis patients.
Material and methods: 17 end-stage osteoarthritis patients and 10 healthy persons were included in the study. Serum level COMP and C2C were measured by ELISA technique.
Results: COMP concentration in the serum end-stage osteoarthritis patients was statistically significantly lower than in the controls. C2C concentration in the serum end-stage osteoarthritis patients was not significantly lower than in the controls. Serum COMP and C2C level were not independent of age of osteoarthritis patients and healthy persons. The ROC curve for COMP suggests that serum concentration of this protein has medium usefulness for diagnosis of end-stage osteoarthritis. The ROC curve for C2C suggests that serum concentration of this biochemical marker has weak usefulness for diagnosis of end-stage osteoarthritis.
Conclusions: Low concentration of COMP and C2C in serum of osteoarthritis patients may suggest significant degradation of articular cartilage in end-stage osteoarthritis. Serum COMP and C2C levels seem not to be useful biochemical markers for laboratory diagnostics and assessment of progression in end-stage osteoarthritis.
Material and methods: 17 end-stage osteoarthritis patients and 10 healthy persons were included in the study. Serum level COMP and C2C were measured by ELISA technique.
Results: COMP concentration in the serum end-stage osteoarthritis patients was statistically significantly lower than in the controls. C2C concentration in the serum end-stage osteoarthritis patients was not significantly lower than in the controls. Serum COMP and C2C level were not independent of age of osteoarthritis patients and healthy persons. The ROC curve for COMP suggests that serum concentration of this protein has medium usefulness for diagnosis of end-stage osteoarthritis. The ROC curve for C2C suggests that serum concentration of this biochemical marker has weak usefulness for diagnosis of end-stage osteoarthritis.
Conclusions: Low concentration of COMP and C2C in serum of osteoarthritis patients may suggest significant degradation of articular cartilage in end-stage osteoarthritis. Serum COMP and C2C levels seem not to be useful biochemical markers for laboratory diagnostics and assessment of progression in end-stage osteoarthritis.
REFERENCES (34)
1.
Klimiuk PA, Sierakowski S, Kita K i wsp. Leczenie choroby zwyrodnieniowej stawów. Nowa Medycyna 2002; 9: 37-43.
2.
Samborski W. Patogeneza choroby zwyrodnieniowej stawów – nowe metody leczenia i miejsce fizjoterapii. Balneologia Polska 2001; 43: 9-16.
3.
Szczęsny G. Patomechanizm powstawania zmian zwyrodnieniowych stawów. Ortop Traum Reh 2002; 4: 222-229.
4.
Otterness IG, Swindell AC, Zimmerer RO, et al. An analysis of 14 molecular markers for monitoring osteoarthritis: segregation of the markers into clusters and distinguishing osteoarthritis at baseline. Osteoarthritis Cartilage 2000; 8: 180-185.
5.
Young-Min SA, Cawston TE, Griffiths ID. Markers of joint destruction: principles, problems, and potential. Ann Rheum Dis 2001; 60: 545-548.
6.
Targońska-Stepniak B. Otyłość a choroba zwyrodnieniowa stawów. Reumatologia 2003; 41: 366-370.
7.
Pelletier JP, Martel-Pelletier J. Therapeutic targets in osteoarthritis: from today to tomorrow with new imaging technology. Ann Rheum Dis 2003; 62 Suppl 2: ii79-82.
8.
Głuszko P. Osteoartroza – najczęstsza choroba stawów. Gerontologia Polska 2003; 11: 3-8.
9.
Christgau S, Cloos P. Cartilage degradation products as markers for evaluation of patients with rheumatic disease. Clin App Immunol Rev 2004; 4: 277-294.
10.
Clark AG, Jordan JM, Vilim V, et al. Serum cartilage oligomeric matrix protein reflects osteoarthritis presence and severity: the Johnston County Osteoarthritis Project. Arthritis Rheum 1999; 42: 2356-2364.
11.
Jordan JM, Luta G, Stabler T, et al. Ethnic and sex differences in serum levels of cartilage oligomeric matrix protein: the Johnston County Osteoarthritis Project. Arthritis Rheum 2003; 48: 675-81.
12.
Roughley PJ, El-Maadawy S. The use of biochemical markers of bone and cartilage metabolism to monitor osteoarthritis – dreams and reality. J Rheumatol 2003; 30: 910-913.
13.
Vilím V, Olejárová M, Machácek S, et al. Serum levels of cartilage oligomeric matrix protein (COMP) correlate with radiographic progression of knee osteoarthritis. Osteoarthritis Cartilage 2002; 10: 707-713.
14.
Garnero P, Piperno M, Gineyts E, et al. Cross sectional evaluation of biochemical markers of bone, cartilage, and synovial tissue metabolism in patients with knee osteoarthritis: relations with disease activity and joint damage. Ann Rheum Dis 2001; 60: 619-626.
15.
Bruyere O, Collette JH, Ethgen O, et al. Biochemical markers of bone and cartilage remodeling in prediction of longterm knee osteoarthrtis. J Rheumatol 2003; 30: 1043-1050.
16.
Wisłowska M, Jabłońska B. Serum cartilage oligomeric matrix protein (COMP) in rheumatoid arthritis and knee osteoarthritis. Clin Rheumatol 2005; 24: 278-284.
17.
Wisłowska M, Jabłońska B. Cartilage Oligomeric Matrix Protein (COMP) w chorobach narządu ruchu. Reumatologia 2004; 42: 573-579.
18.
Vilím V, Vytásek R, Olejárová M, et al. Serum cartilage oligomeric matrix protein reflects the presence of clinically diagnosed synovitis in patients with knee osteoarthritis. Osteoarthritis Cartilage 2001; 9: 612-618.
19.
Felson DT. An update on the pathogenesis and epidemiology of osteoarthritis. Radiol Clin North Am 2004; 42: 1-9. .
20.
Lohmander LS, Felson D. Can we identify a “high risk” patient profile to determine who will experience rapid progression of osteoarthritis? Osteoarthritis Cartilage 2004; 12 Suppl A: S49-S52.
21.
Wollheim FA. Early stages of osteoarthritis: the search for sensitive predictors. Ann Rheum Dis 2003; 62: 1031-1032.
22.
Buckwalter JA, Martin J. Choroba zwyrodnieniowa stawów. Clinical Symposia 1995; 47: 1-32.
23.
Chitnavis J, Sinsheimer JS, Suchard MA, et al. End-stage coxarthrosis and gonarthrosis. Aetiology, clinical patterns and radiological features of idiopathic osteoarthritis. Rheumatology (Oxford) 2000; 39: 612-619.
24.
Imhof H, Czerny C, Gahleitner A, et al. Koxarthrose, Hüftgelenk. Radiologe 2002; 42: 416-431.
25.
Garnero P. Osteoarthritis: biological markers for the future? Joint Bone Spine 2002; 69: 525-530.
26.
Lis K, Odrowąż-Sypniewska G, Biliński P i wsp. Oligomeryczne białko macierzy chrząstki (COMP) i glikoproteina YKL-40 jako markery degradacji chrząstki i procesu zapalnego w chorobie zwyrodnieniowej stawu biodrowego. Diagnostyka Laboratoryjna 2003; 39: 133-141.
27.
Poole AR, Ionescu M, Fitzcharles MA, Billinghurst RC. The assessment of cartilage degradation in vivo: development of an immunoassay for the measurement in body fluids of type II collagen cleaved by collagenases. J Immunol Methods 2004; 294: 145-153.
28.
Conrozier T, Ferrand F, Vignon E, et al. Relationship between serum biomarkers of type II collagen (C2C; C1, 2C and CP II) and radio logical patterns in patient with hip osteoarthritis. Osteoarthritis Cartilage 2005; 5: 38-41.
29.
King KB, Lindsey CT, Dunn TC, et al. A study of the relationship between molecular biomarkers of joint degeneration and the magnetic resonance-measured characteristics of cartilage in 16 symptomatic knees. Magn Reson Imaging 2004; 22: 1117-1123.
30.
Bijlsma JW, Lafeber FP. Radiographic joint damage in rheumatoid arthritis is associated with differences in cartilage turnover and can be predicted by serum biomarkers: en evaluation from 1 to 4 years after diagnosis. Arthritis Res Ther 2006; 8: R31-R32.
31.
Haima P. Biochemical markers for the management of rheumatoid arthritis and osteoarthritis. Clinical and Technical Monograph 2002; dostępne na: http://www.teco-medical.ch/dow....
32.
Elsaid KA, Chichester CO. Review: Collagen markers in early arthritic diseases. Clin Chim Acta 2006; 365: 68-77.
33.
Mazzuca SA, Poole AR, Brandt KD, et al. Associations between joint space narrowing and molecular markers of collagen and proteoglycan turnover in patients with knee osteoarthritis. J Rheumatol 2006; 33: 1147-1151.
34.
Cahue S, Sharma L, Dunlop D, et al. The ratio of type II collagen breakdown to synthesis and its relationship with the progression of knee osteoarthritis. Osteoarthritis Cartilage 2007; 15: 819-823.
Copyright: © Narodowy Instytut Geriatrii, Reumatologii i Rehabilitacji w Warszawie. This is an Open Access journal, all articles are distributed under the terms of the Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International (CC BY-NC-SA 4.0) License (https://creativecommons.org/licenses/by-nc-sa/4.0/), allowing third parties to copy and redistribute the material in any medium or format and to remix, transform, and build upon the material, provided the original work is properly cited and states its license.
Share
RELATED ARTICLE
| eISSN: | 2084-9834 |
| ISSN: | 0034-6233 |
We process personal data collected when visiting the website. The function of obtaining information about users and their behavior is carried out by voluntarily entered information in forms and saving cookies in end devices. Data, including cookies, are used to provide services, improve the user experience and to analyze the traffic in accordance with the Privacy policy. Data are also collected and processed by Google Analytics tool (more).
You can change cookies settings in your browser. Restricted use of cookies in the browser configuration may affect some functionalities of the website.
You can change cookies settings in your browser. Restricted use of cookies in the browser configuration may affect some functionalities of the website.
